Pure red cell aplasia is a rare condition, that can be either idiopathic or associated with a lymphoproliferative disorder. The latter is considered to result from T cell-mediated suppression of haematopoiesis, and usually responds well to treatment with immunosuppressive medication. We describe a patient with B-CLL-associated pure red cell aplasia who did not respond to several courses of immunosuppressive treatment. Erythropoiesis was finally restored after allogeneic bone marrow transplantation. Bone Marrow Transplantation (2001) 27, 771-773. Keywords: pure red cell aplasia; allo-BMT; CLL First described by Kazsnelson, pure red cell aplasia (PRCA) is a rare haematopoietic disorder characterised by selective aplasia of the erythroid cell line in the bone marrow.
First described by Kazsnelson, pure red cell aplasia (PRCA) is a rare haematopoietic disorder characterised by selective aplasia of the erythroid cell line in the bone marrow.
1,2 The syndrome can be either congenital (Diamond-Blackfan anaemia) or acquired. Most cases of acquired PRCA are idiopathic, but a large number of associated illnesses have been described, most notably thymomas and lymphoid malignancies. 3 The association of PRCA with B cell chronic lymphocytic leukaemia (CLL) is well known, and appears to be based on the presence of T␥ suppressor cells. 4, 5 Several studies report good results using immunosuppressive medication, in particular cyclosporin A, for the treatment of CLL-associated PRCA. 6, 7 We describe a patient with B-CLL-associated PRCA, who did not respond to several courses of immunosuppressive treatment. Erythropoiesis was finally restored after T cell-depleted allogeneic bone marrow transplantation.
Case report
A 43-year-old Caucasian man was first diagnosed with PRCA in 1997, when he presented with signs and symp- /l, as were levels of vitamin B12 and folic acid. There was no serologic evidence of recent CMV or EBV infection, serologic and DNA studies for parvovirus B19 infection were negative and diagnostic imaging studies showed no evidence of thymoma. Bone marrow examination was remarkable for the near absence of mature erythroid precursors with paratrabecular clusters of mature lymphocytes on biopsy. Immunophenotyping showed a monoclonal B cell population in blood and bone marrow (CD5
ϩ , weak expression of surface Ig), comprising approximately 35% of the lymphocyte population. Southern blot analysis of IgH genes confirmed the presence of a monoclonal B cell population, whereas no clonal T cell receptor gene rearrangement was detected. Cytogenetic analysis revealed a normal XY karyotype. In vitro colony forming assays showed normal BFU-E and CFU-GM from bone marrow nucleated cells as well as from T cell-depleted bone marrow mononuclear cells. Peripheral blood erythropoietin levels were elevated, but no formal studies were done to exclude antibodies to erythropoietin or erythropoietin receptors. A diagnosis of B-CLL, RAI stage 0 with accompanying PRCA was made.
Initial treatment with chlorambucil and prednisone followed by treatment with cyclosporin A and prednisone had no effect. Evaluation 1 year after diagnosis showed persistent B-CLL (approximately 30% monoclonal B cells in bone marrow) and an ongoing transfusion requirement for red cells. Subsequent treatment with antithymocyte globulin (horse ATG 15 mg/kg/day for 5 days), cyclosporin A and steroids again had no effect on the transfusion requirements. Treatment with cyclophosphamide, vincristine and prednisone (CVP) and subsequently with three courses of fludarabine (25 mg/m 2 /day for 5 days) resulted in near complete resolution of monoclonal B cells from blood and bone marrow, but had no effect on the PRCA. A short trial of erythropoietin and cyclosporin A again failed to reduce the transfusion requirement. Because of the ongoing need for red cell transfusions associated with an increase of serum ferritin, iron chelation therapy with desferroxamine was initiated in 1999.
Bone Marrow Transplantation
Since alternative treatment options were lacking, allogeneic bone marrow transplantation was considered to treat the B-CLL-associated PRCA. Informed consent was obtained and after conditioning with cyclophosphamide (60 mg/kg/day for 2 days) and TBI (10 Gy in two fractions over 2 days with partial lung and kidney shielding), the patient underwent a T cell-depleted allogeneic bone marrow transplant with marrow from his HLA-identical brother. The final graft composition was 1.32 ϫ 10 6 CD34 ϩ cells/kg and 2 ϫ 10 5 CD3 ϩ cells/kg. Cyclosporin A was given to prevent GVHD.
Rapid engraftment ensued, with neutrophils Ͼ0.5 ϫ 10 9 /l, platelets Ͼ20 ϫ 10 9 /l and no red cell transfusion requirement by day ϩ25. Bone marrow examination around that time showed good myelo-and megakaryopoiesis with persistent erythroid hypoplasia. Full donor haematopoiesis was confirmed by PCR analysis of variable number of tandem repeat (VNTR) differences. He was readmitted on day ϩ54 with nausea, diarrhoea, fever and recurrent anaemia with reticulocytopenia. An extensive search for an infectious aetiology yielded no cause and pathological examination of biopsies from the sigmoid and stomach showed no evidence of aGVHD. Symptoms gradually improved. On day ϩ90 signs and symptoms of an upper respiratory tract infection developed. Virologic examination of nasal washings revealed respiratory syncytial virus (RSV) infection. Treatment with nebulized ribavirin was started, resulting in complete resolution of symptoms. Interestingly, his anaemia resolved during ribavirin treatment. Bone marrow examination on day ϩ100 showed 24% erythropoiesis. Evaluation 6 months post transplantation showed a stable haemoglobin (7.2 mmol/l; 8.3 g/dl) without any transfusion requirement and a normal reticulocyte count (40 ϫ 10 9 /l). PCR-VNTR analysis again confirmed 100% donor chimaerism.
Discussion
Autoimmune phenomena are known to occur frequently in B-CLL and are often directed against haematopoietic cells. The available data suggest that T cell-mediated suppression of erythropoiesis represents a secondary event occurring during the course of the disease. 8 Normal growth of BFU-E in vitro (as was the case in our patient) also points towards an immune-mediated inhibition of erythropoiesis, and is generally associated with a good response to immunosuppressive therapy. 9 No curative treatment options are presently available for treating CLL, however, encouraging results have recently been reported on the use of allogeneic stem cell transplantation for younger patients. 10, 11 Whereas bone marrow transplantation has been successful in several cases of congenital hypoplastic anaemia, only one case report describes the use of allogeneic BMT for acquired PRCA. 12, 13 In their case report, Müller et al 13 describe how unmanipulated allogeneic BMT after nonmyeloablative conditioning with cyclophosphamide and ATG initially resulted in complete donor engraftment, but later reversed to full autologous reconstitution.
Although most patients with CLL-associated PRCA respond well to immunosuppressive therapy, occasional patients will fail even the most rigorous immune modulation. Orchard et al 14 describe a patient with myelomaassociated PRCA, who remained red cell transfusiondependent, even after autologous stem cell transplantation. We present a patient with CLL-associated PRCA who failed to respond to all standard treatment modalities including combined immunosuppressive therapy with ATG and cyclosporin A. We were particularly concerned about the onset of transfusion-related iron overload. Indeed, a liver biopsy performed right before transplantation confirmed the presence of early hepatic haemosiderosis. In view of his underlying malignancy, his young age and anticipating a gradual worsening of cardiac and hepatic reserve due to ongoing iron overload, we considered an allogeneic BMT appropriate. The initial lack of erythroid engraftment could be due to recipient T cell-mediated rejection (as is fairly common after T cell-depleted BMT for aplastic anaemia). A possible association with the later diagnosed RSV infection cannot be excluded, as viral infections can interfere with engraftment, but this remains speculative. Interestingly, good erythroid engraftment with documentation of full donor haematopoiesis was achieved after recovery from the RSV infection and is presently ongoing.
